Oncology

News

Immutep investors spooked by LAG-3 failure in lung cancer

Friday the 13th has turned into a horror story for Immutep, whose share price has collapsed after it abandoned a pivotal trial of its LAG-3 drug efti.

News

NICE says no to Genmab cervical cancer therapy

Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.

News

BMS eyes another celmod filing in myeloma after phase 3 win

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

News

Incyte breaks new ground in anal cancer with EU approval

Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

News

Safety concerns prompt Ipsen to pull Tazverik from market

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

Immutep investors spooked by LAG-3 failure in lung cancer

NICE says no to Genmab cervical cancer therapy

BMS eyes another celmod filing in myeloma after phase 3 win

Incyte breaks new ground in anal cancer with EU approval

Roche's oral SERD flunks phase 3 breast cancer test

Safety concerns prompt Ipsen to pull Tazverik from market

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks